Clinical Trials Logo

Filter by:
NCT ID: NCT03869892 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

SOLSTICE
Start date: March 20, 2019
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

NCT ID: NCT03849404 Recruiting - Plaque Psoriasis Clinical Trials

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Start date: February 18, 2019
Phase: Phase 3
Study type: Interventional

Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.

NCT ID: NCT03827018 Recruiting - Clinical trials for Giant Cell Arteritis

KPL-301 for Subjects With Giant Cell Arteritis

Start date: December 21, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

NCT ID: NCT03825380 Recruiting - Glaucoma Clinical Trials

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Start date: November 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

NCT ID: NCT03816956 Recruiting - Clinical trials for Staphylococcus Aureus

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

AR-301-002
Start date: February 2019
Phase: Phase 3
Study type: Interventional

AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.

NCT ID: NCT03805100 Not yet recruiting - Clinical trials for Macular Degeneration

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

XPLORE
Start date: March 2019
Phase: Phase 3
Study type: Interventional

The objectives of this study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).

NCT ID: NCT03793712 Recruiting - Schizophrenia Clinical Trials

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Start date: December 27, 2018
Phase: Phase 2
Study type: Interventional

A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia

NCT ID: NCT03766867 Recruiting - Clinical trials for Major Depressive Disorder

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Start date: December 3, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days

NCT ID: NCT03762850 Recruiting - Clinical trials for Immunoglobulin A Nephropathy

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

PROTECT
Start date: December 20, 2018
Phase: Phase 3
Study type: Interventional

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

NCT ID: NCT03758885 Recruiting - Infertility Clinical Trials

Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

IMPLANT4
Start date: January 10, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.